EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Top Cited Papers
- 20 February 2025
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 43 (3) , 537-551.e7
Abstract
No abstract availableKeywords
Funding Information
- Stichting Lymph&Co
- Parker Institute for Cancer Immunotherapy
- Laffey-McHugh Foundation
- National Cancer Institute (R37-CA-262362-02)
This publication has 85 references indexed in Scilit:
- EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell functionCancer Cell, 2024
- Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1Cell Reports, 2022
- CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacyCancer Immunology, Immunotherapy, 2022
- Exploiting epigenetic dependencies in ovarian cancer therapyInternational Journal of Cancer, 2021
- Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune ResponseCancer Cell, 2020
- Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant LymphomasCell Reports, 2019
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerCancer Cell, 2019
- Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer ImmunityCell Reports, 2018
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid TransformationCancer Cell, 2013